Can Improved Glycemic Control Slow Renal Function Decline at All Stages of Diabetic Nephropathy?

Seminars in Nephrology

Volumn 32, Issue 5, 2012, Pages 423-431

  Goel, Gautam ^a   Perkins, Bruce A ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

diabetic nephropathy; glycemic control; microalbuminuria; renal function loss; Type 1 diabetes

Indexed keywords

ALBUMIN; CYSTATIN C; GLUCOSE; HEMOGLOBIN A1C; INSULIN;

ALBUMINURIA; ARTICLE; CONTINUOUS INFUSION; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; KIDNEY DYSFUNCTION; MACROALBUMINURIA; MEDICAL LITERATURE; MEDICAL RESEARCH; MICROALBUMINURIA; OBSERVATIONAL STUDY; PANCREAS ISLET TRANSPLANTATION; PANCREAS TRANSPLANTATION; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SECONDARY PREVENTION;

ALBUMINURIA; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; GLOMERULAR FILTRATION RATE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 84867355437     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2012.07.004     Document Type: Article

References (56)

1. de Boer I.H., Rue T.C., Cleary P.A., et al. Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Arch Intern Med 2011, 171:412-420.
2. Perkins B.A., Krolewski A.S. Early nephropathy in type 1 diabetes: the importance of early renal function decline. Curr Opin Nephrol Hypertens 2009, 18:233-240.
3. Aschner P., Horton E., Leiter L.A., Munro N., Skyler J.S. Practical steps to improving the management of type 1 diabetes: recommendations from the Global Partnership for Effective Diabetes Management. Int J Clin Pract 2010, 64:305-315.
4. Nathan D.M., Zinman B., Cleary P.A., et al. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch Intern Med 2009, 169:1307-1316.
5. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 2000, 342:381-389.
6. Eldor R., Raz I. The individualized target HbA1c: a new method for improving macrovascular risk and glycemia without hypoglycemia and weight gain. Rev Diabet Stud 2009, 6:6-12.
7. Krolewski A., Bonventre J. High risk of ESRD in type 1 diabetes: new strategies are needed to retard progressive renal function decline. Semin Nephrol 2012, 32:407-414.
8. de Boer I.H., Sun W., Cleary P.A., et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 2011, 365:2366-2376.
9. Perkins B.A., Ficociello L.H., Ostrander B.E., et al. Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes. J Am Soc Nephrol 2007, 18:1353-1361.
10. Perkins B.A., Ficociello L.H., Roshan B., Warram J.H., Krolewski A.S. In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria. Kidney Int 2010, 77:57-64.
11. Viberti G.C., Hill R.D., Jarrett R.J., Argyropoulos A., Mahmud U., Keen H. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1982, 1:1430-1432.
12. Parving H.H., Oxenboll B., Svendsen P.A., Christiansen J.S., Andersen A.R. Early detection of patients at risk of developing diabetic nephropathy. A longitudinal study of urinary albumin excretion. Acta Endocrinol (Copenh) 1982, 100:550-555.
13. Mogensen C.E., Christensen C.K. Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 1984, 311:89-93.
14. Perkins B.A., Ficociello L.H., Silva K.H., Finkelstein D.M., Warram J.H., Krolewski A.S. Regression of microalbuminuria in type 1 diabetes. N Engl J Med 2003, 348:2285-2293.
15. Dubin R., Shlipak M., Li Y., et al. Racial differences in the association of pentraxin-3 with kidney dysfunction: the Multi-Ethnic Study of Atherosclerosis. Nephrol Dial Transplant 2011, 26:1903-1908.
16. Araki S., Haneda M., Sugimoto T., et al. Factors associated with frequent remission of microalbuminuria in patients with type 2 diabetes. Diabetes 2005, 54:2983-2987.
17. Giorgino F., Laviola L., Cavallo Perin P., Solnica B., Fuller J., Chaturvedi N. Factors associated with progression to macroalbuminuria in microalbuminuric type 1 diabetic patients: the EURODIAB Prospective Complications Study. Diabetologia 2004, 47:1020-1028.
18. Ficociello L.H., Perkins B.A., Silva K.H., et al. Determinants of progression from microalbuminuria to proteinuria in patients who have type 1 diabetes and are treated with angiotensin-converting enzyme inhibitors. Clin J Am Soc Nephrol 2007, 2:461-469.
19. Amin R., Widmer B., Prevost A.T., et al. Risk of microalbuminuria and progression to macroalbuminuria in a cohort with childhood onset type 1 diabetes: prospective observational study. BMJ 2008, 336:697-701.
20. Premaratne E., MacIsaac R.J., Finch S., Panagiotopoulos S., Ekinci E., Jerums G. Serial measurements of cystatin C are more accurate than creatinine-based methods in detecting declining renal function in type 1 diabetes. Diabetes Care 2008, 31:971-973.
21. Perkins B.A., Nelson R.G., Ostrander B.E., et al. Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study. J Am Soc Nephrol 2005, 16:1404-1412.
22. Lindeman R.D., Tobin J., Shock N.W. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985, 33:278-285.
23. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993, 329:977-986.
24. Molitch M.E., Steffes M., Sun W., et al. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care 2010, 33:1536-1543.
25. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003, 290:2159-2167.
26. Perkins B.A., Krolewski A.S. Early nephropathy in type 1 diabetes: a new perspective on who will and who will not progress. Curr Diab Rep 2005, 5:455-463.
27. Cherney D.Z., Reich H.N., Miller J.A., et al. Age is a determinant of acute hemodynamic responses to hyperglycemia and angiotensin II in humans with uncomplicated type 1 diabetes mellitus. Am J Physiol Regul Integr Comp Physiol 2010, 299:R206-R214.
28. Rosolowsky E.T., Skupien J., Smiles A.M., et al. Risk for ESRD in type 1 diabetes remains high despite renoprotection. J Am Soc Nephrol 2011, 22:545-553.
29. van Ballegooie E., de Jong P.E., Donker A.J., Sluiter W.J. The effect of continuous subcutaneous insulin infusion on renal function in type I diabetic patients with and without proteinuria. Proc Eur Dial Transplant Assoc Eur Ren Assoc 1985, 21:722-724.
30. Bangstad H.J., Osterby R., Dahl-Jorgensen K., Berg K.J., Hartmann A., Hanssen K.F. Improvement of blood glucose control in IDDM patients retards the progression of morphological changes in early diabetic nephropathy. Diabetologia 1994, 37:483-490.
31. Dahl-Jorgensen K., Brinchmann-Hansen O., Hanssen K.F., et al. Effect of near normoglycaemia for two years on progression of early diabetic retinopathy, nephropathy, and neuropathy: the Oslo study. Br Med J (Clin Res Ed) 1986, 293:1195-1199.
32. Dahl-Jorgensen K., Bjoro T., Kierulf P., Sandvik L., Bangstad H.J., Hanssen K.F. Long-term glycemic control and kidney function in insulin-dependent diabetes mellitus. Kidney Int 1992, 41:920-923.
33. Intensive therapy and progression to clinical albuminuria in patients with insulin dependent diabetes mellitus and microalbuminuria. Microalbuminuria Collaborative Study Group, United Kingdom. BMJ 1995, 311:973-977.
34. Feldt-Rasmussen B., Mathiesen E.R., Hegedus L., Deckert T. Kidney function during 12 months of strict metabolic control in insulin-dependent diabetic patients with incipient nephropathy. N Engl J Med 1986, 314:665-670.
35. Feldt-Rasmussen B., Mathiesen E.R., Jensen T., Lauritzen T., Deckert T. Effect of improved metabolic control on loss of kidney function in type 1 (insulin-dependent) diabetic patients: an update of the Steno studies. Diabetologia 1991, 34:164-170.
36. Blood glucose control and the evolution of diabetic retinopathy and albuminuria. A preliminary multicenter trial. The Kroc Collaborative Study Group. N Engl J Med 1984, 311:365-372.
37. Breyer J.A. Diabetic nephropathy in insulin-dependent patients. Am J Kidney Dis 1992, 20:533-547.
38. Bending J.J., Viberti G.C., Watkins P.J., Keen H. Intermittent clinical proteinuria and renal function in diabetes: evolution and the effect of glycaemic control. Br Med J (Clin Res Ed) 1986, 292:83-86.
39. Ciavarella A., Vannini P., Flammini M., Bacci L., Forlani G., Borgnino L.C. Effect of long-term near-normoglycemia on the progression of diabetic nephropathy. Diabete Metab 1985, 11:3-8.
40. Cantarovich D., Perrone V. Pancreas transplant as treatment to arrest renal function decline in patients with type 1 diabetes and proteinuria. Semin Nephrol 2012, 32:432-436.
41. Shapiro A.M., Ricordi C., Hering B.J., et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006, 355:1318-1330.
42. Senior P.A., Zeman M., Paty B.W., Ryan E.A., Shapiro A.M. Changes in renal function after clinical islet transplantation: four-year observational study. Am J Transplant 2007, 7:91-98.
43. Leitao C.B., Cure P., Messinger S., et al. Stable renal function after islet transplantation: importance of patient selection and aggressive clinical management. Transplantation 2009, 87:681-688.
44. Fioretto P., Steffes M.W., Sutherland D.E., Goetz F.C., Mauer M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998, 339:69-75.
45. Resource utilization and costs of care in the diabetes control and complications trial. Diabetes Care 1995, 18:1468-1478.
46. Reichard P. A risk-benefit assessment of conventional versus intensive insulin therapy. Drug Saf 1994, 10:196-202.
47. Gerstein H.C., Miller M.E., Byington R.P., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559.
48. Shurraw S., Hemmelgarn B., Lin M., et al. Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study. Arch Intern Med 2011, 171:1920-1927.
49. Gohda T., Niewczas M.A., Ficociello L.H., Walker W.H., Skupien J., Rosetti F., et al. Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes. J Am Soc Nephrol 2012, 23:516-524.
50. Niewczas M.A., Gohda T., Skupien J., Smiles A.M., Walker W.H., Rosetti F., et al. Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. J Am Soc Nephrol 2012, 23:507-515.
51. Tamborlane W.V., Beck R.W., Bode B.W., et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008, 359:1464-1476.
52. Pickup J.C., Freeman S.C., Sutton A.J. Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data. BMJ 2011, 343:d3805.
53. Misso M.L., Egberts K.J., Page M., O'Connor D., Shaw J. Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database Syst Rev 2010, 1. CD005103.
54. Retnakaran R., Hochman J., DeVries J.H., et al. Continuous subcutaneous insulin infusion versus multiple daily injections: the impact of baseline A1c. Diabetes Care 2004, 27:2590-2596.
55. Bergenstal R.M., Tamborlane W.V., Ahmann A., et al. Sensor-augmented pump therapy for A1C reduction (STAR 3) study: results from the 6-month continuation phase. Diabetes Care 2011, 34:2403-2405.
56. Bergenstal R.M., Tamborlane W.V., Ahmann A., et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med 2010, 363:311-320.